Table 1 Baseline characteristics of the IMPROVED study population
Total n = 610 | Early remission n = 387 | Arm 1 n = 83 | Arm 2 n = 78 | OOP n = 50 | |
|---|---|---|---|---|---|
DAS, mean ± SD | 3.2 ± 0.9 | 3.0 ± 0.8 | 3.6 ± 0.9 | 3.6 ± 1.0 | 3.6 ± 0.9 |
HAQ, mean ± SD | 1.2 ± 0.7 | 1.0 ± 0.7 | 1.4 ± 0.6 | 1.4 ± 0.6 | 1.3 ± 0.7 |
Age in years, mean ± SD | 52 ± 14 | 52 ± 14 | 49 ± 14 | 51 ± 14 | 54 ± 14 |
Female, n (%) | 414 (68) | 240 (62) | 64 (77) | 58 (74) | 42 (84) |
Symptom duration (weeks), median (IQR) | 18 (9–32) | 17 (9–30) | 22 (9–41) | 21 (8–31) | 18 (9–42) |
RF-positive, n (%) | 339 (56) | 224 (58) | 41 (49) | 43 (55) | 23 (46) |
ACPA-positive, n (%) | 333 (55) | 225 (58) | 40 (48) | 37 (47) | 25 (50) |
RA (2010 criteria), n (%) | 479 (79) | 298 (77) | 66 (80) | 66 (85) | 40 (80) |
Swollen joint count, median (IQR) | 5 (3–10) | 5 (2–9) | 6 (3–10) | 8 (4–12) | 7 (3–13) |
Tender joint count, median (IQR) | 6 (4–9) | 5 (3–8) | 8 (6–13) | 9 (6–13) | 8 (6–14) |
ESR mm/h, median (IQR) | 25 (11–39) | 23 (8–38) | 28 (13–41) | 22 (11–41) | 29 (16–42) |
VAS global health (mm), mean ± SD | 46 ± 23 | 43 ± 24 | 53 ± 20 | 54 ± 22 | 49 ± 23 |
Total SHS, median (IQR) | 0 (0–1.0) | 0 (0–0.5) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
Erosive, n (%) | 89 (15) | 63 (16) | 10 (12) | 13 (17) | 3 (6) |